The Virtual Patient: Developing Drugs Using Modeling and Simulation
In recent years, many major pharmaceutical companies have established dedicated groups for modeling and simulation (M&S). M&S aims to use quantitative approaches to bridge the gaps between medicine, pharmacology, statistics, and computer science in drug development. This trend is supported by the Food and Drug Administration (FDA) and its Critical Path Initiative, which strongly encourages model-based drug development.
Some content is only viewable by ASA Members. Please login or become an ASA member to gain access.
